11400
K. Kubota et al. / Tetrahedron 62 (2006) 11397–11401
DRX-300orBrukerDRX-400(100 MHz)spectrometerusing
CDCl3 (77.0 ppm), C6D6 (128.0 ppm), or DMSO-d6
(40.5 ppm) as internal standard. Infrared spectra were re-
corded on a Perkin Elmer Paragon 1000 FTIR spectrometer.
Low-resolutionmassspectrawereobtainedonaJEOLHX110
mass spectrometer in the Columbia University Mass Spec-
trometry Laboratory. Optical rotations were obtained on a
JASCO DIP-1000 polarimeter using a 10 cm path length cell.
chromatography (100% pentane/20% Et2O/pentane) to af-
ford the pure bicyclic aldehyde products in the yields and
enantioselectivities indicated in Table 2.
4.2.1. Diels–Alder reaction products—characterization
and determination of enantioselectivity.
4.2.1.1. Table 2, entry 1. The physical and spectral data
for this compound matched previously reported data.12 The
diastereoselectivity (exo:endo ratio ¼ 96:4) was determined
1
4.1.1. Synthesis of ligand 7f. The Schiff base formed by
condensation of cyclohexanediamine monotosylamide and
salicylaldehyde has been prepared and characterized previ-
ously.11 We prepared the (R,R)-cyclohexanediamine-derived
Schiff base according to this procedure. To a cooled (0 ꢁC)
solution of this Schiff base (3.0 mmol) in CH2Cl2 (4.0 mL)
and MeOH (12.0 mL) was added NaBH4 (337 mg,
9.0 mmol). The reaction mixture was warmed to room tem-
perature after 15 min and stirred for an additional 3 h. The re-
action was then quenched by the addition of 1 M NaOH
(15 mL). The aqueous layer was extracted with CH2Cl2
(3ꢂ10 mL) and the combined organic layers were washed
with brine (1ꢂ5 mL), dried over MgSO4, filtered, and
concentrated. The solid residue was then purified by recrys-
tallization (Et2O/CH2Cl2) to afford 1.01 g (90%) of ligand
by H NMR (400 MHz, CDCl3) integration: d 9.69 (s, 1H,
CHO, exo), 9.39 (s, 1H, CHO, endo). The enantioselectivity
(ee ¼ 94%) was determined by reduction with NaBH4 to the
corresponding alcohol, conversion to the (R)-MTPA ester
1
1
derivative, and H NMR integration: H NMR (500 MHz,
CDCl3) d 4.34 (d, 1H, one of CH2O-(R)-MTPA, major),
4.31 (d, 1H, one of CH2O-(R)-MTPA, minor), 4.25 (d, 1H,
one of CH2O-(R)-MTPA, minor), 4.22 (d, 1H, one of
CH2O-(R)-MTPA, major).
4.2.1.2. Table 2, entry 2. The physical and spectral data
for this compound matched previously reported data.13 The
diastereoselectivity (exo:endo ratio>98:2) was determined
1
by H NMR (400 MHz, CDCl3) integration: d 9.62 (s, 1H,
CHO, exo), 9.37 (s, 1H, CHO, endo). The enantioselectivity
(ee ¼ 90%) was determined by reduction with NaBH4 to the
corresponding alcohol, conversion to the (R)-MTPA ester
1
7f as a white solid. [a]2D1 +9.77 (c 1.00, CH2Cl2); H NMR
(400 MHz, CDCl3) d 7.74 (dd, 2H, J¼5.0 Hz, 1.6 Hz,
SO2C6(o-H2)(m-H2)CH3), 7.24 (d, 2H, J¼7.9 Hz,
SO2C6(o-H2)(m-H2)CH3), 7.15 (dt, 1H, J¼1.5 Hz, 7.7 Hz,
one of NCH2C6H4), 6.91 (dd, 1H, J¼1.3 Hz, 6.1 Hz, one of
NCH2C6H4), 6.81–6.73 (m, 2H, two of NCH2C6H4), 4.67
(br s, 1H, NHSO2Ar), 3.93 (d, 1H, J¼13.9 Hz, one of
NCH2Ar), 3.84 (d, 1H, J¼13.9 Hz, one of NCH2Ar), 3.02–
2.95 (br m, 1H, CHNHSO2Ar), 2.37 (s, 3H, SO2C6H4CH3),
2.31–2.26 (m, 1H, CHNHCH2Ar), 2.14–2.08 (br m, 1H,
Cy–H), 1.70–1.58 (br m, 3H, Cy–H3), 1.23–1.12 (m, 4H,
Cy–H4); 13C NMR (75 MHz, CDCl3) d 158.0, 143.7,
137.6, 129.8, 129.8, 128.5, 128.0, 126.9, 126.9, 123.1,
119.0, 116.4, 60.9, 57.1, 50.0, 33.4, 31.1, 24.8, 24.0, 21.5;
IR (KBr) 3319, 3237, 3043, 2932, 2857, 1613, 1590, 1478,
1449, 1411, 1322, 1262, 1150, 1091, 934, 912, 748, 666,
547 cmꢀ1; HRMS (FAB+) calculated for C20H27N2O3S
[M+H]+ 375.1742, found 375.1733.
1
1
derivative, and H NMR integration: H NMR (500 MHz,
CDCl3) d 4.31 (d, 1H, one of CH2O-(R)-MTPA, major),
4.25 (d, 1H, one of CH2O-(R)-MTPA, minor), 4.20 (d, 1H,
one of CH2O-(R)-MTPA, minor), 4.14 (d, 1H, one of
CH2O-(R)-MTPA, major). The absolute configuration was
assigned by analogy to the methacrolein reaction.
4.2.1.3. Table 2, entry 3. The physical and spectral data
for this compound matched previously reported data.14 The
diastereoselectivity (exo:endo ratio>96:4) was determined
1
by H NMR (400 MHz, CDCl3) integration: d 9.73 (s, 1H,
CHO, exo), 9.45 (s, 1H, CHO, endo). The enantioselectivity
(ee ¼ 86%) was determined by reduction with NaBH4 to the
corresponding alcohol, conversion to the (R)-MTPA ester
1
1
derivative, and H NMR integration: H NMR (500 MHz,
CDCl3) d 2.68 (br s, 1H, ]CH–CH, major), 2.63 (br s,
1H, ]CH–CH, minor).
4.2. General procedure for the Diels–Alder reactions in
Table 2
4.2.1.4. Table 2, entry 4. The physical and spectral data
for this compound matched previously reported data.13 The
diastereoselectivity (exo:endo ratio>95:5) was determined
To a cooled (ꢀ78 ꢁC) solution of SiCl4 (149 mL, 1.30 mmol)
and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (612 mL,
4.09 mmol) in CH2Cl2 (13.0 mL) is added a solution of 7f
(500 mg, 1.33 mmol) in CH2Cl2 (13.0 mL). The reaction
mixture is slowly warmed to room temperature over the
course of 4 h, and after an additional 4 h at room tempera-
ture, the resulting solution of the catalyst 8f in CH2Cl2
(0.0500 M) is used directly for the Diels–Alder reactions.
1
by H NMR (400 MHz, CDCl3) integration: d 9.70 (s, 1H,
CHO, exo), 9.42 (s, 1H, CHO, endo). The enantioselectivity
(ee ¼ 54%) was determined by reduction with NaBH4 to the
corresponding alcohol, conversion to the (R)-MTPA ester
1
1
derivative, and H NMR integration: H NMR (500 MHz,
CDCl3) d 4.41 (d, 1H, one of CH2O-(R)-MTPA, minor),
4.37 (d, 1H, one of CH2O-(R)-MTPA, minor), 4.33 (d, 1H,
one of CH2O-(R)-MTPA, major), 4.29 (d, 1H, one of
CH2O-(R)-MTPA, minor). The absolute configuration was
assigned by analogy to the methacrolein reaction.
To a cooled (ꢀ78 ꢁC) solution of catalyst 8f (0.05 M in
CH2Cl2, 4.0 mL, 0.20 mmol) and cyclopentadiene (250 mL,
3.8 mmol) is added the unsaturated aldehyde (1.0 mmol)
dropwise. After the indicated reaction time (see Table 2),
the mixture is diluted with CH2Cl2 (1.0 mL) and quenched
with a solution of 4:1 MeOH/H2O (250 mL). The organic
layer is washed with brine (1ꢂ1 mL), dried over Na2SO4,
and concentrated. The residue is purified by flash
Acknowledgements
This work was supported by grants from the National Insti-
tutes of Health (NIGMS GM58133) and the National